{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T21:25:41Z","timestamp":1783286741869,"version":"3.54.6"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the JSPS Grant-in-Aid for Scientific Research","award":["20K10508"],"award-info":[{"award-number":["20K10508"]}]},{"name":"the JSPS Grant-in-Aid for Scientific Research","award":["17K08705"],"award-info":[{"award-number":["17K08705"]}]},{"name":"the JSPS Grant-in-Aid for Scientific Research","award":["19K09873"],"award-info":[{"award-number":["19K09873"]}]},{"name":"the JSPS Grant-in-Aid for Scientific Research","award":["19K16568"],"award-info":[{"award-number":["19K16568"]}]},{"name":"the JSPS Grant-in-Aid for Scientific Research","award":["20K07597"],"award-info":[{"award-number":["20K07597"]}]},{"name":"the JSPS Grant-in-Aid for Scientific Research","award":["18K09386"],"award-info":[{"award-number":["18K09386"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although immune-checkpoint inhibitors (ICIs) are effective against various cancers, little is known regarding their role in salivary gland carcinoma (SGC) treatment. Therefore, we evaluated the efficacy and safety of nivolumab monotherapy in patients with recurrent and\/or metastatic SGC. In this multicentre retrospective study, nivolumab (240\u00a0mg) was administered every 2\u00a0weeks. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety were examined; the correlation between treatment outcomes and clinicopathological factors was analysed. Twenty-four patients were enrolled; the most common histopathology was salivary duct carcinoma. Eleven tumours were PD-L1-positive; no tumour was microsatellite instability-high. The ORR was 4.2%, and the median PFS and OS were 1.6 and 10.7\u00a0months, respectively. One patient continued nivolumab for 28\u00a0months without disease progression. One patient showed grade 4 increase in creatine phosphokinase levels and grade 3 myositis. Biomarker analysis revealed significantly increased OS in patients with performance status of 0; modified Glasgow prognostic score of 0; low neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and C-reactive protein; and high lymphocyte-to-monocyte ratio and in patients who received systemic therapy following nivolumab. Although nivolumab\u2019s efficacy against SGC was limited, some patients achieved long-term disease control. Further studies are warranted on ICI use for SGC.<\/jats:p>","DOI":"10.1038\/s41598-020-73965-6","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T10:02:42Z","timestamp":1602496962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Kazutomo","family":"Niwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saotome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaku","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Masubuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirooki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Oridate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"73965_CR1","unstructured":"Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry.) https:\/\/ganjoho.jp\/data\/reg_stat\/statistics\/dl\/cancer_incidenceNCR(2016-2017).xls. Accessed 28 September 2020."},{"key":"73965_CR2","volume-title":"WHO Classification of Head and Neck Tumours","author":"AK El-Naggar","year":"2017","unstructured":"El-Naggar, A. K. et al. WHO Classification of Head and Neck Tumours 4th edn. (IARC, Lyon, 2017).","edition":"4"},{"key":"73965_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.otc.2015.11.001","volume":"49","author":"AG Lewis","year":"2016","unstructured":"Lewis, A. G., Tong, T. & Maghami, E. Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol. Clin. N. Am. 49, 343\u2013380 (2016).","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"73965_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102069","author":"MJM Uijen","year":"2020","unstructured":"Uijen, M. J. M. et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. Cancer Treat. Rev. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102069 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"73965_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi, H. et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J. Clin. Oncol. 37, 125\u2013134 (2019).","journal-title":"J. Clin. Oncol."},{"key":"73965_CR6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","volume":"30","author":"KL Jhaveri","year":"2019","unstructured":"Jhaveri, K. L. et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann. Oncol. 30, 1821\u20131830 (2019).","journal-title":"Ann. Oncol."},{"key":"73965_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","volume":"31","author":"R Kurzrock","year":"2020","unstructured":"Kurzrock, R. et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study. Ann. Oncol. 31, 412\u2013421 (2020).","journal-title":"Ann. Oncol."},{"key":"73965_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","volume":"10","author":"J Tsurutani","year":"2020","unstructured":"Tsurutani, J. et al. Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 10, 688\u2013701 (2020).","journal-title":"Cancer Discov."},{"key":"73965_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hed.23940","volume":"38","author":"LD Locati","year":"2016","unstructured":"Locati, L. D. et al. Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 38, 724\u2013731 (2016).","journal-title":"Head Neck."},{"key":"73965_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi, C. et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann. Oncol. 29, 979\u2013984 (2018).","journal-title":"Ann. Oncol."},{"key":"73965_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hed.25035","volume":"40","author":"E Boon","year":"2018","unstructured":"Boon, E. et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck. 40, 605\u2013613 (2018).","journal-title":"Head Neck."},{"key":"73965_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3389\/fonc.2019.00701","volume":"9","author":"PV Viscuse","year":"2019","unstructured":"Viscuse, P. V. et al. First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma\u2014A retrospective study. Front. Oncol. 9, 701 (2019).","journal-title":"Front. Oncol."},{"key":"73965_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 21, 531\u2013540 (2020).","journal-title":"Lancet Oncol."},{"key":"73965_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 21, 271\u2013282 (2020).","journal-title":"Lancet Oncol."},{"key":"73965_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian, V. et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J. Clin. Oncol. 37, 1529\u20131537 (2019).","journal-title":"J. Clin. Oncol."},{"key":"73965_CR16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/cncr.32754","volume":"126","author":"LD Locati","year":"2020","unstructured":"Locati, L. D. et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer 126, 1888\u20131894 (2020).","journal-title":"Cancer"},{"key":"73965_CR17","doi-asserted-by":"publisher","first-page":"v465","DOI":"10.1093\/annonc\/mdz252.040","volume":"30","author":"R Ferrarotto","year":"2019","unstructured":"Ferrarotto, R. et al. Vergara-Silva. ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data. Ann. Oncol. 30, v465\u2013v466 (2019).","journal-title":"Ann. Oncol."},{"key":"73965_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/cncr.32792","volume":"126","author":"X Mimica","year":"2020","unstructured":"Mimica, X. et al. Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. Cancer 126, 2153\u20132162 (2020).","journal-title":"Cancer"},{"key":"73965_CR19","doi-asserted-by":"publisher","first-page":"104690","DOI":"10.1016\/j.oraloncology.2020.104690","volume":"106","author":"GJ Hanna","year":"2020","unstructured":"Hanna, G. J. et al. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 106, 104690 (2020).","journal-title":"Oral Oncol."},{"key":"73965_CR20","first-page":"173","volume-title":"WHO Classification of Head and Neck Tumours","author":"T Nagao","year":"2017","unstructured":"Nagao, T., Licitra, L., Loening, T., Vielh, P. & Williams, M. D. Salivary duct carcinoma. In WHO Classification of Head and Neck Tumours 4th edn (eds Naggar, A. K. et al.) 173\u2013174 (Lyon, IARC, 2017).","edition":"4"},{"key":"73965_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22288","author":"M Nakaguro","year":"2020","unstructured":"Nakaguro, M. et al. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytol. https:\/\/doi.org\/10.1002\/cncy.22288 (2020).","journal-title":"Cancer Cytol."},{"key":"73965_CR22","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"73965_CR23","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"73965_CR24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","volume":"41","author":"RB Cohen","year":"2018","unstructured":"Cohen, R. B. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: Findings of the phase 1b KEYNOTE-028 study. Am. J. Clin. Oncol. 41, 1083\u20131088 (2018).","journal-title":"Am. J. Clin. Oncol."},{"key":"73965_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez, C. P. et al. A Phase II Trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin. Cancer Res. 26, 837\u2013845 (2020).","journal-title":"Clin. Cancer Res."},{"key":"73965_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091317","author":"R Hori","year":"2019","unstructured":"Hori, R. et al. Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11091317 (2019).","journal-title":"Cancers (Basel)."},{"key":"73965_CR27","doi-asserted-by":"publisher","first-page":"104359","DOI":"10.1016\/j.oraloncology.2019.07.002","volume":"101","author":"S Kokkali","year":"2020","unstructured":"Kokkali, S. et al. Nivolumab in patients with rare head and neck carcinomas: A single center\u2019s experience. Oral Oncol. 101, 104359 (2020).","journal-title":"Oral Oncol."},{"key":"73965_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer. 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer."},{"key":"73965_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-Cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"73965_CR30","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"73965_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"73965_CR32","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho, A. S. et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J. Clin. Investig. 129, 4276\u20134289 (2019).","journal-title":"J. Clin. Investig."},{"key":"73965_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.oraloncology.2019.01.015","volume":"90","author":"T Nakano","year":"2019","unstructured":"Nakano, T. et al. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncol. 90, 30\u201337 (2019).","journal-title":"Oral Oncol."},{"key":"73965_CR34","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1002\/cam4.2602","volume":"8","author":"SM Gargano","year":"2019","unstructured":"Gargano, S. M. et al. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 8, 7322\u20137329 (2019).","journal-title":"Cancer Med."},{"key":"73965_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jso.24266","volume":"114","author":"T Mukaigawa","year":"2016","unstructured":"Mukaigawa, T. et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J. Surg. Oncol. 114, 36\u201343 (2016).","journal-title":"J. Surg. Oncol."},{"key":"73965_CR36","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2147\/OTT.S134589","volume":"10","author":"H Chang","year":"2017","unstructured":"Chang, H. et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Oncol. Targets Ther. 10, 2983\u20132992 (2017).","journal-title":"Oncol. Targets Ther."},{"key":"73965_CR37","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1002\/hed.25857","volume":"41","author":"M Szewczyk","year":"2019","unstructured":"Szewczyk, M. et al. Prognostic markers in salivary gland cancer and their impact on survival. Head Neck. 41, 3338\u20133347 (2019).","journal-title":"Head Neck."},{"key":"73965_CR38","doi-asserted-by":"publisher","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","volume":"9","author":"D Vital","year":"2019","unstructured":"Vital, D. et al. The expression of PD-L1 in salivary gland carcinomas. Sci. Rep. 9, 12724 (2019).","journal-title":"Sci. Rep."},{"key":"73965_CR39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3758","author":"M Linxweiler","year":"2020","unstructured":"Linxweiler, M. et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3758 (2020).","journal-title":"Clin. Cancer Res."},{"key":"73965_CR40","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","volume":"22","author":"MG Dalin","year":"2016","unstructured":"Dalin, M. G. et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin. Cancer Res. 22, 4623\u20134633 (2016).","journal-title":"Clin. Cancer Res."},{"key":"73965_CR41","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","volume":"28","author":"JS Ross","year":"2017","unstructured":"Ross, J. S. et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann. Oncol. 28, 2539\u20132546 (2017).","journal-title":"Ann. Oncol."},{"key":"73965_CR42","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","volume":"138","author":"J Terzi\u0107","year":"2010","unstructured":"Terzi\u0107, J., Grivennikov, S., Karin, E. & Karin, M. Inflammation and colon cancer. Gastroenterology 138, 2101-2114.e5 (2010).","journal-title":"Gastroenterology"},{"key":"73965_CR43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.18632\/oncotarget.13565","volume":"8","author":"D Kawakita","year":"2017","unstructured":"Kawakita, D. et al. Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: A multi-institutional study in Japan. Oncotarget. 8, 1083\u20131091 (2017).","journal-title":"Oncotarget."},{"key":"73965_CR44","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl Cancer Inst. 106, dju124 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"73965_CR45","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci, P. F. et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann. Oncol. 27, 732\u2013738 (2016).","journal-title":"Ann. Oncol."},{"key":"73965_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3124","author":"T Matsuki","year":"2020","unstructured":"Matsuki, T. et al. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.3124 (2020).","journal-title":"Cancer Med."},{"key":"73965_CR47","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens, A. et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 22, 2908\u20132918 (2016).","journal-title":"Clin. Cancer Res."},{"key":"73965_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jjco\/hyz168","volume":"50","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto, Y. et al. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J. Clin. Oncol. 50, 214\u2013220 (2020).","journal-title":"Jpn J. Clin. Oncol."},{"key":"73965_CR49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem, S. et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 111, 176\u2013181 (2017).","journal-title":"Lung Cancer."},{"key":"73965_CR50","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","volume":"24","author":"J Delyon","year":"2013","unstructured":"Delyon, J. et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 24, 1697\u20131703 (2013).","journal-title":"Ann. Oncol."},{"key":"73965_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","volume":"13","author":"J Tanizaki","year":"2018","unstructured":"Tanizaki, J. et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J. Thorac. Oncol. 13, 97\u2013105 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"73965_CR52","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956\u2013965 (2016).","journal-title":"Lancet Oncol."},{"key":"73965_CR53","doi-asserted-by":"crossref","first-page":"CT021","DOI":"10.1158\/1538-7445.AM2017-CT021","volume":"77","author":"RL Ferris","year":"2017","unstructured":"Ferris, R. L. et al. Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141. Cancer Res. 77, CT021 (2017).","journal-title":"Cancer Res."},{"key":"73965_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1200\/JCO.2005.02.7227","volume":"24","author":"O Buhard","year":"2006","unstructured":"Buhard, O. et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J. Clin. Oncol. 24, 241\u2013251 (2006).","journal-title":"J. Clin. Oncol."},{"key":"73965_CR55","doi-asserted-by":"publisher","first-page":"59023","DOI":"10.18632\/oncotarget.19812","volume":"8","author":"S Takase","year":"2017","unstructured":"Takase, S. et al. Biomarker immunoprofile in salivary duct carcinomas: Clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 8, 59023\u201359035 (2017).","journal-title":"Oncotarget."},{"key":"73965_CR56","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997\u20134013 (2013).","journal-title":"J. Clin. Oncol."},{"key":"73965_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST Guideline (Version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer."},{"key":"73965_CR58","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73965-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:48:18Z","timestamp":1670359698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73965"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73965-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16988"}}